FDA recently approved the first 4-strain, cell culture-derived, inactivated seasonal flu vaccine available in the United States. Flucelvax Quadrivalent influenza vaccine (Seqirus) helps protect against the 2 influenza A viruses and two B viruses recommended by the World Health Organization (WHO) and the FDA for the current influenza season.
In a major new entry in the diabetes market, FDA just approved linagliptin and metformin hydrochloride extended-release tablets (Jentadueto XR, Boehringer Ingelheim and Eli Lilly and Company) to treat type 2 diabetes.
Novo Nordisk’s new diabetes drug production facility in Clayton, N.C., will ensure production capacity for these drugs in the United States for the decade ahead.
A systemic review highlights studies that improved medication adherence and patient outcomes using strategies that could be effective if employed in real-world healthcare settings.
FDA recently granted accelerated approval for atezolizumab (Tecentriq, Genentech), the first drug for bladder cancer that utilizes the body’s immune system. The drug will be available by early June.
FDA has approved lenvatinib (Lenvima, Eisai Inc.) in combination with everolimus for the treatment of advanced renal cell carcinoma.
In alarming news for diabetic patients taking canagliflozin (Invokana, Invokamet) medications, FDA is warning that interim safety results from an ongoing clinical trial found an increase in foot and leg amputations with the drugs.
Nivolumab (Opdivo, Bristol-Myers Squibb) received two new approvals from FDA to treat two different cancers.
After heavy criticism by Congress, presidential candidates and others, Valeant Pharmaceuticals is offering a discount program on its heart drugs Nitropress and Isuprel.
There's a growing need for improved access to medication-assisted treatment among patients with opioid use disorder, according to a new study presented at the American Society of Addiction Medicine 47th Annual Conference.
If a proposed Vermont bill is successful, drug companies would have to explain why they hiked prices on certain drugs.
FDA issued a new warning about potentially serious side effects associated with fluoroquinolone antibacterial drugs. Affected brands include Cipro, Levaquin, Avelox, Factive and Moxaflaxacin injection, as well as the generic Ofloxacin.
FDA is warning that the antipsychotic medicine olanzapine can cause a rare but serious skin reaction that can progress to affect other parts of the body.
FDA recently fast-tracked approval of cabozantinib (Cabometyx, Exelixis, Inc.) to treat advanced renal cell carcinoma. Here are the top 5 facts to know about Cabometyx.
Express Scripts will implement more programs that pay for drugs based on their effectiveness, according to the PBM’s chief medical officer Steve Miller, MD. Simultaneously, the PBM plans to implement a spending cap on diabetes medications.
FDA approved the first drug to hallucinations and delusions associated with psychosis experienced by some people with Parkinson’s disease.
The first US test for the Zika virus is available after Quest Diagnostics received an Emergency Use Authorization (EUA) for its Zika Virus RNA Qualitative Real-Time RT-PCR test (Zika RT-PCR test).
FDA recently approved a new indication for afatinib (Gilotrif, Boehringer Ingelheim) for patients with squamous cell carcinoma of the lung. The once-daily tablets are now indicated for the treatment of patients with the lung cancer, whose disease has progressed after treatment with platinum-based chemotherapy. Here are the top 6 facts to know about Gilotrif.
FDA expanded the use of ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets without ribavirin (Viekira Pak, AbbVie) this week to treat patients with genotype 1b (GT1b) chronic hepatitis C virus (HCV) infection and compensated cirrhosis (Child-Pugh A).
Surprisingly, Medicare beneficiaries are likely to pay much more for biosimilars than the referenced brand medication, according to a new report.
The generic metformin (Mallinkrodt) significantly reduced the risk of dying from heart attack and stroke compared to other common diabetes medications, according to a new study.
FDA took the unusual step of withdrawing approval of two cholesterol-lowering drugs late last week.
As organizations and politicians continue to sound the alarm that drug prices are rising, another new report confirmed the trend. Total spending on medicines in the US reached $310 billion in 2015 on an estimated net price basis, up 8.5 percent from the previous year, according to a new report from the IMS Institute for Healthcare Informatics.
FDA advisory committee recently voted to recommend approval of obeticholic acid (Ocaliva, Intercept Pharmaceuticals, Inc.) for the treatment of primary biliary cholangitis (PBC). If approved, Ocaliva would be the first new treatment for PBC in nearly 20 years.
